<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Serum concentrations of salicylazosulphapyridine (SASP), <z:chebi fb="0" ids="132842">sulphapyridine</z:chebi> (SP), and <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) were measured in 64 outpatients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>About 90% of the patients in remission had serum total SP concentrations above 20 mug/ml </plain></SENT>
<SENT sid="2" pm="."><plain>Seven patients, however, had active disease despite a serum total SP concentration &gt; 20 mug/ml </plain></SENT>
<SENT sid="3" pm="."><plain>The SASP and the individual SP metabolites did not show any correlation with the disease state </plain></SENT>
<SENT sid="4" pm="."><plain>Three g per day seems to be the most effective dose </plain></SENT>
<SENT sid="5" pm="."><plain>Plain and enteric-coated tablets produced similar concentrations at equivalent dosage </plain></SENT>
<SENT sid="6" pm="."><plain>Side effects due to SASP were frequent in patients who had a total SP concentration &gt; 50 mug/ml of serum </plain></SENT>
</text></document>